Cytokinetics Inc

11 de set. de 2026, 20:08 UTC

Cytokinetics Inc shares are higher as analysts express positive sentiments, with Cantor Fitzgerald reiterating an Overweight rating and a price target of $112 from Truist.

9 de set. de 2026, 19:36 UTC

Cytokinetics Inc shares are lower today amid rising crude oil prices and inflation concerns. The stock is currently below its 20-day moving average.

8 de set. de 2026, 23:56 UTC

Cytokinetics Inc shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report and rising interest rate expectations.

4 de set. de 2026, 23:51 UTC

Cytokinetics Inc shares are higher in after-market trading, reaching their highest cumulative return of the day, despite no specific news driving the move.

3 de set. de 2026, 19:26 UTC

Cytokinetics Inc is trading higher as it announces participation in investor conferences and highlights an upcoming Supplemental New Drug Application for aficamten.

2 de set. de 2026, 23:16 UTC

Cytokinetics Inc shares are trading lower after-market following its investor conference announcements, with Ionis Pharmaceuticals' decline possibly impacting sentiment in the sector.

1 de set. de 2026, 20:09 UTC

Cytokinetics Inc shares are higher as Truist and H.C. Wainwright reaffirm Buy ratings, citing positive momentum and potential from recent ESC conference insights.

31 de ago. de 2026, 23:01 UTC

Cytokinetics Inc shares are lower in after-market trading amid broader market declines. Concerns over potential interest rate hikes may be influencing the downward trend.

28 de ago. de 2026, 22:01 UTC

Cytokinetics Inc shares are higher after announcing positive Phase 3 trial results for aficamten at the European Society of Cardiology Congress.

26 de ago. de 2026, 20:08 UTC

Cytokinetics shares advance amid social media discussions of a $100 price target, reflecting gains since Tuesday's close despite mixed U.S. market performance.

14 de ago. de 2026, 19:26 UTC

Cytokinetics shares are higher as H.C. Wainwright maintains a Buy rating and Barclays raises its price target to $110 amid strong sales momentum.

13 de ago. de 2026, 23:21 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from three consecutive lower sessions, though still below the 20-day moving average.

12 de ago. de 2026, 19:46 UTC

Cytokinetics Inc shares are lower today, continuing a decline since Tuesday's close. No specific news was identified to explain the movement.

11 de ago. de 2026, 19:11 UTC

Cytokinetics Inc shares declined as CEO Robert I. Blum sold 7,500 shares at $76.76, raising investor concerns about executive confidence in the company.

10 de ago. de 2026, 19:46 UTC

Cytokinetics shares rise as Truist upgrades rating and raises price target to $112, while Citizens increases its target to $110 following strong Q2 results.

8 de ago. de 2026, 00:01 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from earlier declines. The stock remains below its 20-day moving average.

7 de ago. de 2026, 22:51 UTC

Cytokinetics shares are rising in after-market trading, recovering from earlier session lows amid positive sentiment in US equities and mixed labor data.

6 de ago. de 2026, 23:21 UTC

Cytokinetics reports Q2 2026 net loss of $198.8 million, better than expected. Shares are higher in after-market trading amid positive sentiment.

5 de ago. de 2026, 20:06 UTC

Cytokinetics Inc shares are higher amid positive market sentiment and easing crude oil prices, despite a shift from recent daily closing trends.

4 de ago. de 2026, 23:01 UTC

Cytokinetics Inc is higher in after-market trading, gaining since Tuesday's close, though still below its 20-day moving average with no specific news identified.

3 de ago. de 2026, 19:36 UTC

Cytokinetics Inc shares are lower amid broader market trends influenced by geopolitical developments. Earlier in the session, shares pulled back from a session high.

31 de jul. de 2026, 20:02 UTC

Cytokinetics Inc is lower today amid a broader decline in the Biotechnology sub-sector, reversing a trend of higher daily closes since Thursday.

30 de jul. de 2026, 18:46 UTC

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

29 de jul. de 2026, 20:41 UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

28 de jul. de 2026, 19:06 UTC

Cytokinetics shares are lower amid investor concerns over CEO Robert I. Blum's recent stock option exercise and sale, reported earlier today.

27 de jul. de 2026, 19:56 UTC

Cytokinetics Inc shares are lower, continuing a recent decline, amid social media discussions of a $103 price target and anticipated Myqorzo earnings in 2026.

24 de jul. de 2026, 23:46 UTC

Cytokinetics Inc shares are lower in after-market hours, continuing recent weakness after three consecutive daily declines. No specific news was identified for the move.

22 de jul. de 2026, 23:16 UTC

Cytokinetics Inc shares are lower in after-market hours amid broader market weakness, with no specific news identified to explain the decline.

21 de jul. de 2026, 18:16 UTC

Cytokinetics Inc is trading higher, with no specific news identified. The stock has gained since Monday amid rising commodity prices, particularly copper and oil.

20 de jul. de 2026, 19:22 UTC

Cytokinetics shares are lower amid declines in the Biotechnology sector. Myqorzo revenue expectations exceed consensus, with a long-term projection of $1.67 billion by 2030.